Lv5
1020 积分 2024-03-01 加入
Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial
2个月前
已完结
Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial
2个月前
已完结
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
2个月前
已完结
Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study
2个月前
已完结
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
2个月前
已完结
The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP‐1/GIP receptor agonist (BGM0504) in healthy volunteers: A dose‐escalation Phase I study
2个月前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
2个月前
已完结
The effects of canagliflozin in type 2 diabetes in subgroups defined by population‐specific body mass index: Insights from the CANVAS Program and CREDENCE trial
2个月前
已完结
SGLT inhibitors on weight and body mass: A meta‐analysis of 116 randomized‐controlled trials
2个月前
已完结
Association between obesity and periodontitis in Australian adults: A single mediation analysis
4个月前
已完结
皖公网安备34019202002308
